News

Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
Medical Dialogues1h
AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report
Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...
The Pharma Letter22h
AstraZeneca in talks with Summit for over $15 billion license deal
UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...
11 Best Hot Stocks to Buy According to Wall Street Analysts
Summit Therapeutics Inc. (NASDAQ: SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, ...
The Manila Times on MSN16h
AstraZeneca eyes licensing lung cancer drug
ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...
Stocks fade as tariff deadline looms large
Stocks fade as tariff deadline looms large - US President Donald Trump said he plans to start sending letters informing ...